Companies /Healthcare

Macrogenics Inc

NASDAQ: MGNX Biotechnology
$2.05
▼ $0.12 (−5.53%) today
Markets closed · 5:38pm ET

MGNX at a Glance

Valuation
Market cap
$138.7M
Profitability
Revenue (TTM)
$140.8M
Profit margin
-36.6%
EPS (TTM)
$-2.25
Price
52-week range
$1 – $5
Street target
$8.00

Headquartered in Rockville, MD Fiscal year ends December NASDAQ: MGNX macrogenics.com

About MacroGenics

MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based cancer therapeutics using its proprietary antibody engineering platforms. Its pipeline spans several modalities. It is developing topoisomerase I inhibitor-based antibody-drug conjugates (ADCs): MGC028 (ADAM9), MGC026 (B7-H3) and MGC030 (an undisclosed antigen). It is also developing T-cell engagers, including the preclinical MGD032. Its dual checkpoint inhibitor, lorigerlimab, is a PD-1 × CTLA-4 bispecific DART molecule being studied in gynecologic cancers. The company earns revenue from collaborations and asset sales with partners such as Gilead, Sanofi (Provention) and Incyte, through milestones, option exercises and royalties, notably ZYNYZ royalties. It has sold its GMP/CDMO manufacturing operations to Bora, now reported as discontinued operations, to focus on oncology drug development. Updated

Latest Activity

MGNXMacroGenics
Q3 2026
EPS
-$0.32
est -$0.13-151.6%
Revenue
$19M
est $39M-52.4%

The revenue miss is lumpy partner math: last year's quarter carried a $50 million Sanofi milestone, this one only a $10 million Gilead option payment. What matters more is the $287.7 million cash pile against a $146 million market cap, funding operations through 2028 and into ADC readouts for MGC028 and MGC026 in 2027.

Quarterly EPS — reported vs estimate

MGNX Coverage

Frequently Asked Questions

What does MacroGenics do?

MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based cancer therapeutics using its proprietary antibody engineering platforms. Its pipeline spans several modalities.

What is the MGNX stock price target?

The Wall Street consensus 12-month price target for MGNX is $8.00.